Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genenta Science S.p.A. (NASDAQ: GNTA) SEC filings page on Stock Titan brings together the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a foreign private issuer and clinical-stage immuno-oncology company, Genenta reports key information about its Temferon™ development programs, financing activities, and governance through Form 6-K and related filings.
In these filings, investors can find unaudited consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations, which outline Genenta’s cash resources, operating expenses, and funding runway in relation to its solid tumor clinical programs. Other 6-Ks describe registered direct offerings of American Depositary Shares under a shelf registration statement on Form F-3, including purchase agreements, placement agency agreements, and use-of-proceeds language.
Genenta also uses SEC filings to document a Mandatory Convertible Bond financing with ENEA Tech and Biomedical, amendments to its by-laws, changes in the size and composition of its Board of Directors, and executive leadership transitions such as the appointment or resignation of a Chief Medical Officer. Shareholder meeting notices and outcomes, including approvals of statutory financial statements and director appointments, are similarly detailed in these reports.
Through Stock Titan, users can access Genenta’s 6-Ks, registration statements, prospectus supplements, and related exhibits as they are made available on EDGAR, along with AI-powered summaries that explain the practical meaning of each document. This includes highlighting where Genenta discusses its Temferon clinical trials in glioblastoma multiforme and metastatic renal cell carcinoma, capital structure changes, and material agreements with manufacturing partners. For those monitoring insider holdings, the SEC database also provides ownership and transaction reports that complement the company’s own ownership updates.
Use this page to quickly review GNTA’s latest SEC filings, compare new disclosures with prior reports, and understand how regulatory documents reflect the evolution of Genenta’s immuno-oncology platform and corporate strategy.
Genenta Science S.p.A. (GNTA) entered into a registered direct offering of 4,285,715 ADSs at $3.50 per ADS, for gross proceeds of approximately $15.0 million, expected to close on or about October 28, 2025 subject to customary conditions. Each ADS represents one ordinary share.
The company plans to use net proceeds for working capital and general corporate purposes. The sale is being made under a prospectus supplement to Genenta’s effective Form F-3 shelf.
Maxim Group LLC (lead) and Rodman & Renshaw LLC (co-placement agent) are acting as placement agents; Genenta will pay a 6.0% cash fee on aggregate gross proceeds and up to $75,000 for expenses. For 90 days after closing, the company, and separately its officers and directors under lock-up agreements, agree to restrictions on issuing or selling company securities, with limited exceptions. The company also agreed not to conduct variable rate transactions for six months.
Genenta Science S.p.A. (GNTA) reported outcomes from its April 29, 2025 Annual Ordinary Shareholders’ Meeting. Shareholders approved the statutory financial statements for the year ended December 31, 2024, audited by Revicom.
They appointed three directors effective April 29, 2025, adding Dr. Francesco Galimi as a new member. Armon R. Sharei, Ph.D. continued on the Board, and Pierluigi Paracchi continued as Chairman. The term of office for each newly appointed director is one year.
The aggregate annual directors’ compensation was set at €105,000. On April 30, 2025, the directors appointed Mr. Paracchi as Chief Executive Officer and allocated annual compensation of €45,000 for the CEO and €30,000 for each of Dr. Galimi and Dr. Sharei.
Genenta Science S.p.A. filed a Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2025 and for the six months ended June 30, 2025. These interim results give a mid-year view of the company’s financial position and performance.
The filing also includes Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same six-month period, offering management’s narrative on the numbers. The Form 6-K is incorporated by reference into Genenta’s existing shelf registration statement on Form F-3, linking these updated financials to potential future securities offerings.
Genenta Science S.p.A. reports a leadership change in its medical and development functions. On September 30, 2025, Carlo Russo, MD, resigned as Chief Medical Officer and Head of Development, effective immediately, after the Company waived any notice period required under his employment agreement. The Company states that his resignation was for personal reasons and did not arise from any disagreement with the Company.
On the same date, Dr. Francesco Galimi, age 58, was appointed acting Chief Medical Officer and Head of Development, effective immediately. He has served on Genenta’s Board of Directors since April 2025 and brings over 30 years of healthcare R&D experience, including senior roles at Adicet Bio, Amgen, Onyx Pharmaceuticals, and GNF/Novartis. Dr. Galimi holds an M.D. with a specialty in Medical Oncology and a Ph.D. in Oncology from the University of Torino Medical School and completed post-doctoral research at the Salk Institute.
Genenta Science S.p.A. has called an Ordinary and Extraordinary Shareholders’ Meeting for October 29, 2025 in virtual format, with a second-call date on October 30, 2025 if needed. Shareholders will be asked to approve amendments to Article 4 of the company’s by-laws to expand its corporate purpose to include all sectors covered by Italian Golden Power legislation.
They will also vote on increasing the Board of Directors from three to five members and on the appointment of two new board members. The notice of meeting and related materials are to be posted on Genenta’s website under the Investors section on or about September 10, 2025.